Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients
Evaluation of Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients: a Cross-sectional Case-control Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Amr Ahmed, Lecturer
- Phone Number: 02/01007065530
- Email: amr.hamed@med.sohag.edu.eg
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- RA according to the American College of Rheumatology (ACR)/EULAR 2010 criteria (Aletaha et al., 2010)
- Age≥18 years
Exclusion Criteria:
- History of hepatitis B and C virus infection.
- Receiving hepatotoxic drugs other than RA-specific drugs.
- Alcohol abuse (i30 g/day in men and ⩾20 g/day in women).
- Diagnosis of Wilson's disease, α1-antitrypsin deficiency or hemochromatosis.
- Autoimmune liver disease.
- Cancer.
- Pregnancy.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
control
|
studying degree of steatosis
|
|
Rheumatoid arthritis patients
|
studying degree of steatosis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
degree of hepatic steatosis
Time Frame: 1 day during examination
|
degree of hepatic steatosis by ultrasonography and Hepatic Steatosis Index.
|
1 day during examination
|
|
degree of hepatic fibrosis
Time Frame: 1 day during examination
|
degree of hepatic fibrosis by FIB-4 and APRI tests
|
1 day during examination
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Soh-Med-22-11-17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.